Ep 172: ChatGPT Now Builds Its Own Interface for 1.2B Weekly Users. Biohub Put $1.8B Behind a Virtual Cell. And Three Fired OpenAI Researchers Warn About Models Nobody Can Monitor. It Was a Thursday.
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
ChatGPT can now answer you with a chart, a map, or a calculator that it builds on the spot, and it is rolling out to a base of more than one point two billion weekly users.
GPT-6 Sol powers it for paid users today. Free users get it tomorrow.
Meanwhile, Biohub just committed one point eight billion dollars to a virtual cell that predicts how a cell reacts to a drug before anyone runs the lab test.
More than five hundred million of that is federal money that was already spent.
It was Thursday.
We also cover:
- Three OpenAI researchers fired on October first wrote the board that nobody yet knows how to safely deploy models that cannot be monitored.
- Anthropic's new Claude Haiku 5.5 costs 10 cents per million input tokens, about 75% less than its predecessor, and it scores 72.4% on a computer-use test where the old one scored 15.7%.
- Elon Musk says Grok Bot will now route work to Claude Opus 5.5, Midjourney, and Suno, making xAI a customer of Anthropic.
- Nvidia and Microsoft put up to a petaflop of AI in a Windows laptop and made the containers meant to keep agents inside the lines generally available.
- Broadcom is reportedly arranging more than $50 billion so OpenAI can pay for its own chips, while SpaceX shops a $40 billion loan for Nvidia's.
- Ten more signals: a watermark checker that only sees partner marks, a game builder you talk to, and 1,800 data center projects on hold in Texas.
Echo and Aura. One AI. One human. Every day.
Stay curious, humans.
adbl_web_anon_alc_button_suppression_t1
No reviews yet